A5044550876- RNA Research and Splicing
- Nerve injury and regeneration
- RNA Interference and Gene Delivery
- Cytokine Signaling Pathways and Interactions
- Melanoma and MAPK Pathways
- Parkinson's Disease Mechanisms and Treatments
- MicroRNA in disease regulation
- Cellular Mechanics and Interactions
- Neurological disorders and treatments
Friedrich-Alexander-Universität Erlangen-Nürnberg
2022-2024
Melanoma is a highly heterogeneous cancer, in which frequent changes activation of signaling pathways lead to high adaptability ever changing tumor microenvironments. The elucidation cancer specific great importance, as demonstrated by the inhibitor common BrafV600E mutation PLX4032 melanoma treatment. We therefore investigated that were influenced neurotrophin NRN1, has been shown be upregulated melanoma.
Alpha synuclein (aSyn) and its aggregation are crucial for the neurodegeneration of Parkinson’s disease (PD). aSyn was initially described in nucleus presynaptic nerve terminals. However, biology nuclear link between subcellular compartments less understood. Current knowledge suggests existence various species with distinct structural biochemical properties. Here, we identified a C-terminal-targeting antibody (Nu-aSyn-C), which has high immunoaffinity towards nucleus. Comparing Nu-aSyn-C to...
In malignant melanoma, a highly aggressive form of skin cancer, many microRNAs are aberrantly expressed contributing to tumorigenesis and progression. Further, deregulation microRNA processing enzymes, like the miRNA-binding protein Argonaute 2, significantly impacts function. This study characterizes novel splice variant Argonaut AGO2-ex1/3. AGO2-ex1/3 is substantially in different melanoma cell lines patient-derived tissue samples. It mature mRNA, which translated into an N-terminally...